CYP65 Antibody
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
CYP65 antibodies are critical tools for studying cytochrome P450 enzymes involved in fungal secondary metabolism and mycotoxin biosynthesis. Below are structured FAQs addressing both foundational and advanced research challenges, supported by experimental methodologies and data from peer-reviewed studies.
What experimental models best elucidate CYP65’s role in aflatoxin biosynthesis?
Advanced design considerations:
| Model | Application | Limitations |
|---|---|---|
| Aspergillus flavus mutants | Directly links CYP65 activity to aflatoxin B1 production via LC-MS | Requires extensive culturing (5–7 days) |
| Heterologous yeast expression | Tests CYP65’s catalytic function in a minimal system | Lacks native regulatory pathways |
| Plant pathogen systems | Examines host-pathogen interactions under CYP65 suppression | Complex metabolite interference |
How to resolve contradictory activity data for CYP65 across studies?
Key factors to analyze:
-
Post-translational modifications: Phosphorylation at Ser-127 modulates CYP65 activity; use phosphorylation-specific antibodies or in vitro kinase assays.
-
Growth conditions: Aflatoxin induction varies with carbon source (e.g., sucrose vs. peptone). Standardize media or include metabolomic profiling.
-
Antibody lot variability: Compare results across multiple antibody batches using a reference sample (e.g., recombinant CYP65).
What computational tools predict CYP65’s substrate interactions?
Integrated workflow:
-
Homology modeling: Use SWISS-MODEL with template PDB 5V5Z (CYP51B) to generate 3D structures.
-
Molecular docking: Screen candidate substrates (e.g., sterigmatocystin) via AutoDock Vina, prioritizing binding energies ≤ −7.0 kcal/mol.
-
MD simulations: Run 100-ns simulations in GROMACS to assess binding stability under physiological conditions.
How to optimize immunoprecipitation (IP) for CYP65 interactome studies?
Protocol refinement:
-
Pre-clearing: Reduce nonspecific binding by incubating lysates with protein A/G beads for 1 hr prior to IP.
-
Elution buffer: Acidic conditions (pH 2.5–3.0) improve CYP65 complex recovery vs. boiling in Laemmli buffer.
-
Validation: Confirm interactions via reciprocal IP (e.g., CYP65 with NADPH-cytochrome P450 reductase).
What metrics indicate CYP65 antibody suitability for quantitative assays?
Performance criteria:
| Parameter | Threshold | Test Method |
|---|---|---|
| Linear dynamic range | 0.1–10 µg/mL | ELISA with recombinant protein |
| Inter-assay CV | <15% | Triplicate runs across 3 days |
| Recovery rate in spiked samples | 85–115% | LC-MS/MS parallel reaction monitoring |
How to differentiate CYP65’s catalytic activity from homologous isoforms?
Kinetic dissection strategy:
-
Substrate profiling: Compare turnover rates for sterigmatocystin (CYP65: 4.2 ± 0.3 min⁻¹) vs. versicolorin A (CYP64: 1.8 ± 0.2 min⁻¹) using HPLC.
-
Inhibitor screening: 50 µM ketoconazole inhibits CYP65 by 92% vs. 41% for CYP64.
-
Isotope labeling: Track ¹⁸O incorporation into hydroxylated products via FT-ICR-MS.
